

Article

The $\alpha 1$ Antagonist Doxazosin Alters the Behavioral Effects of Cocaine in Rats

Colin N. Haile, Yanli Hao, Patrick O'Malley, Thomas F. Newton and Therese A. Kosten *

Michael E. DeBakey VA Medical Center, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA; E-Mails: chaile@bcm.edu (C.N.H.); haoyanli26@yahoo.com (Y.H.); pwomalle@bcm.edu (P.O.); tnewton@bcm.edu (T.F.N.)

* Author to whom correspondence should be addressed; E-Mail: tkosten@bcm.edu; Tel.: +1-713-791-7637; Fax: +1-713-794-7240.

Received: 20 September 2012; in revised form: 26 October 2012 / Accepted: 8 November 2012 / Published: 13 November 2012

Abstract: Medications that target norepinephrine (NE) neurotransmission alter the behavioral effects of cocaine and may be beneficial for stimulant-use disorders. We showed previously that the short-acting, $\alpha 1$ -adrenergic antagonist, prazosin, blocked drug-induced reinstatement of cocaine-seeking in rats and doxazosin (DOX), a longer-acting $\alpha 1$ antagonist blocked cocaine's subjective effects in cocaine-dependent volunteers. To further characterize DOX as a possible pharmacotherapy for cocaine dependence, we assessed its impact on the development and expression of cocaine-induced locomotor sensitization in rats. Rats ($n = 6-8$) were administered saline, cocaine (COC, 10 mg/kg) or DOX (0.3 or 1.0 mg/kg) alone or in combination for 5 consecutive days (development). Following 10-days of drug withdrawal, all rats were administered COC and locomotor activity was again assessed (expression). COC increased locomotor activity across days indicative of sensitization. The high dose (1.0 mg/kg), but not the low dose (0.3 mg/kg) of DOX significantly decreased the development and expression of COC sensitization. DOX alone did not differ from saline. These results are consistent with studies showing that $\alpha 1$ receptors are essential for the development and expression of cocaine's behavioral effects. Results also suggest that blockade of both the development and expression of locomotor sensitization may be important characteristics of possible pharmacotherapies for cocaine dependence in humans.

Keywords: cocaine dependence; psychostimulants; norepinephrine; dopamine; locomotor sensitization

1. Introduction

Cocaine addiction is a chronic relapsing brain disease for which there are no FDA-approved treatments. The prevailing consensus is that cocaine's powerful reinforcing effects in humans (e.g., euphoria, heightened alertness, increased energy levels) are mediated by its ability to increase central monoamines (dopamine, DA, norepinephrine, NE, and serotonin) via transporter blockade within the mesocorticolimbic system [1,2]. This system consists of DAergic neurons in the ventral tegmentum (VTA) that project to the nucleus accumbens (NAc) and prefrontal cortex (PFC) among other areas. Increases in synaptic DA levels within the NAc are critical to cocaine's powerful reinforcing effects [3–5]. Neuroplastic changes secondary to chronic cocaine exposure result in augmented NAc DA and behavior termed sensitization that is hypothesized to relate to various aspects of dependency in humans [6–8]. Unfortunately, decades of preclinical and clinical drug development research focused on DA has not lead to a single medication with proven efficacy prompting the consideration of other possible therapeutic targets [9].

A much-neglected facet of cocaine's action is its effects on brain NE and its relationship with, and ability to modulate, DA neurotransmission [10]. For example, NEergic fibers from the A2 region of the nucleus tractus solitarius and the primary NE cell body region, locus coeruleus (LC), innervate the shell region of the NAc where DA plays a critical role in mediating the behavioral effects of cocaine [4,11]. DA and NE are co-released in cortical brain regions where NE transporters can sequester DA [12,13]. LC projections also innervate the VTA and PFC. Accordingly, ablating the LC attenuates stimulant-induced locomotor activation [14]. Under certain circumstances descending excitatory PFC projections responsible for DA release in the NAc are influenced by NE [15]. Moreover, depletion of NE in the PFC eliminates stimulant-induced DA release in the NAc and cocaine-induced locomotor activation [16]. Consistent with these findings, studies in animals and humans show disulfiram, a drug that eliminates NE by inhibiting the enzyme dopamine β -hydroxylase responsible for its synthesis, alters cocaine's behavioral effects in animals and modestly decreases cocaine use in humans [17,18].

Accumulating evidence supports the notion that the behavioral effects of psychostimulants attributed to NE are primarily due to activation of adrenergic α 1 receptors (α 1R). Infusion of the prototypical α 1R antagonist prazosin into the PFC prevents DA release in the NAc and mice devoid of α 1Rs have compromised stimulant-induced NAc DA release and are insensitive to the behavioral effects of cocaine [19–21]. Cocaine administration protocols that induce sensitization increase α 1R levels and pharmacological antagonism with prazosin blocks the expression of acute activation and sensitization [22–24]. Further, our group and others have demonstrated that prazosin attenuates cocaine self-administration including procedures that model relapse to cocaine-seeking [25–27]. Taken together, these studies suggest that prazosin may be useful in treating cocaine dependence in humans.

Although ample preclinical evidence supports prazosin as a possible therapy, it has a half-life of approximately 2–3 h in humans so multiple doses per day would be required to achieve a therapeutic effect thus limiting its clinical utility. A more viable alternative medication is doxazosin (DOX), an α 1R antagonist with similar affinity for α 1Rs as prazosin, but with a half-life of approximately 11 h making it better suited for once daily dosing [28]. More importantly, we recently confirmed the

possible therapeutic utility of DOX by assessing its impact on cocaine's subjective effects in non-treatment seeking cocaine-dependent individuals [29].

Preliminary clinical studies appear encouraging but the impact of DOX on the behavioral effects of cocaine in animals is presently unknown. A greater understanding of how DOX may alter cocaine's effects in animal models is critical to further its development. Therefore, the primary goal of the present study was to assess how DOX would alter the development and expression of cocaine-induced locomotor sensitization using an established behavioral paradigm [30].


2. Results and Discussion

2.1. Development of Locomotor Sensitization to Cocaine (Development, Days 1–5)

Figure 1A,B shows locomotor activity and vertical counts on the habituation day (HAB) before treatments were begun and the effects of DOX on the development (Days 1–5) of cocaine-induced locomotor sensitization. Although not readily apparent from the figure, the DOX groups differed in baseline distances traveled on the HAB day before the start of the experiment. This statement is supported by a significant main effect for DOX group ($F(2,37) = 14.04, p < 0.0001$). Specifically, the two groups that would be administered the higher dose of DOX showed lower locomotor activity on the habituation day compared to the other groups, $p < 0.01$. There was no difference across COC groups, $p > 0.10$. Due to these baseline effects, data were also analyzed using Analysis of Co-variance (ANOCOVA). Distance traveled was greater among groups that received COC on Day 1 compared to the saline group. This is supported by a significant main effect for treatment among groups ($F(1,37) = 34.66, p < 0.001$). Pair-wise multiple comparisons revealed no differences among groups that received DOX alone and saline ($ps > 0.05$). Close examination of Figure 1 (Day 1) does show however, that the DOX 0.3 + COC treated group traveled greater distance than DOX 0.3 alone ($p < 0.05$).

Distance traveled among groups that received COC was greater over days compared to those that received saline. This is supported by significant main effect for COC ($F(1,37) = 88.98, p < 0.0001$) and Day ($F(4,148) = 3.14, p = 0.05$) and by the COC \times Day interaction ($F(4,148) = 5.53, p = 0.005$). As indicated in Figure 1, repeated administration of COC increased distance traveled over days 2–5 compared to day 1 (pair-wise multiple comparisons, $ps < 0.001$) indicating cocaine-induced sensitization. Groups that received different doses of DOX + COC traveled greater distance over days compared to those that received DOX 0.3 mg/kg and 1.0 mg/kg alone or saline. This is supported by a significant interaction of COC \times DOX ($F(2,37) = 3.26, p < 0.05$). DOX administration alone did not affect gross locomotor activity across days compared to saline; the main effect of DOX was not significant nor were any of its interaction effects, $ps > 0.10$. Results of the ANOCOVA also showed a significant main effect of COC, $F(1,37) = 15.54; p < 0.0005$, and a significant interaction of COC \times DOX, $F(2,37) = 7.37; p < 0.005$.

Figure 1. The development of cocaine locomotor sensitization is presented as mean \pm standard error of mean (SEM) locomotor activity assessed as (A) distance traveled (cm) and (B) vertical counts over 5 consecutive days of drug treatments. Groups of rats (N) were administered vehicle (\circ), cocaine (\bullet , COC; 10 mg/kg; intraperitoneally, IP), doxazosin (\square , DOX; 0.3 or Δ , 1.0 mg/kg, IP), or the combination of DOX 0.3 (\blacksquare) and 1.0 (\blacktriangle) plus COC. DOX alone did not affect gross locomotor activity compared to saline. DOX (1.0 mg/kg) significantly blocked the development of COC-induced increases in vertical counts (B) across days.




The number of rears (vertical counts) exhibited on the HAB day did not differ by COC or by DOX group, $p > 0.10$. Thus, these data were not subjected to analysis by ANOCOVA. There was also no effect of COC or DOX on numbers of rears exhibited on DAY 1 ($p > 0.01$). Cocaine administration increased numbers of rears as supported by the significant COC effect, $F(1,37) = 60.47$; $p < 0.0001$. As seen in Figure 1B, the groups that were administered cocaine reared more than the groups administered saline. Numbers of rears differed across days as supported by the significant DAY effect, $F(4,148) = 3.20$; $p < 0.5$. In addition, there was a trend for the effect of COC on numbers of rears to change over days as suggested by the trend towards significance for the COC \times DAY interaction, $F(4,148) = 2.40$; $p < 0.06$. In general, numbers of rears increased over days in groups administered cocaine. This is seen by comparing the numbers of rears in the COC groups on Day 1 to Day 2 (Figure 1B). Treatment with the higher DOX dose decreased numbers of rears induced by cocaine (Figure 1B). This statement is supported by the significant main effect of DOX, $F(2,37) = 10.37$; $p < 0.005$, and by the COC \times DOX interaction, $F(2,37) = 5.54$; $p < 0.01$.

2.2. Expression of Locomotor Sensitization to Cocaine (Day 15 Drug Challenge)

Ten days following cessation of drug treatments (drug washout) all rats were administered COC (10 mg/kg) to assess the expression of behavioral sensitization. As seen in Figure 2, distance traveled on day 15 differs among the treatment groups following an acute COC injection. Groups previously administered cocaine during the development phase showed greater locomotor activity than the groups that did not have this exposure. This is supported by the significant main effect of COC ($F(1,7) = 15.54, p < 0.0005$). This increase in expression of sensitization to the locomotor effects of cocaine was significantly reduced by DOX. This is supported by the significant COC \times DOX interaction effect, $F(2,37) = 7.37; p < 0.01$, although the main effect of DOX failed to reach significance, $p > 0.10$.

Figure 2. The expression of cocaine locomotor sensitization is presented as mean \pm standard error of mean (SEM) locomotor activity assessed as (A) distance traveled (cm) and (B) vertical counts on the cocaine challenge test day in which all rats were administered cocaine (COC, 10 mg/kg). This test was performed 10 days after termination of the drug treatments. The groups (N) had previously received 5 consecutive days of vehicle, cocaine, doxazosin (DOX; 0.3 or 1.0 mg/kg, IP), or the combination of DOX plus cocaine. DOX significantly altered the expression of cocaine-induced sensitization as exhibited by decreased in distance traveled (A) and vertical counts (B) (DOX main effect $p < 0.0001$; COC \times DOX interaction $p < 0.001$). * Significant difference from saline ($p < 0.05$) and ^ significant difference from COC 10 mg/kg ($p < 0.05$).



The data on expression of sensitization in numbers of rears is shown in Figure 2B. Prior cocaine exposure tended to increase number of vertical counts (rears) as seen by the trend towards significance for the main effect of COC, $F(1,37) = 3.47$; $p < 0.08$. Prior DOX exposure significantly altered the numbers of vertical counts seen in this expression test as supported by the main effect of DOX, $F(2,37) = 19.15$; $p < 0.0001$. The COC \times DOX interaction was also significant, $F(2,37) = 9.22$; $p < 0.001$. As seen in Figure 2B, prior exposure to the low dose of DOX alone led to an increase in rearing whereas prior exposure to the high dose of DOX alone led to a decrease in vertical counts relative to the saline alone group. Of the three groups with prior COC exposure, DOX had a dose-dependent effect to decrease numbers of vertical counts. This is further supported by Newman-Keuls *post hoc* analysis (distance traveled: significant difference between COC alone and DOX 0.03 + COC and DOX 1.0 + COC, $ps < 0.05$; vertical counts: significant difference between COC alone and DOX 1.0 + COC, $p < 0.05$).

The results of the present study demonstrate that pretreatment with the high DOX dose (1.0 mg/kg) effectively blocked the development (days 1–5) and expression (day 15, challenge) of COC-induced locomotor sensitization. This effect was more robustly demonstrated for vertical counts compared to distance traveled. The ability of DOX to block sensitization to cocaine is likely due to specific antagonism of the effects of COC and not due to gross disruption of activity. This conclusion is supported by several findings in the present study. First, distance traveled and vertical counts in the DOX alone groups were no different from that of the saline group. Second, the blockade of the expression of COC-induced sensitization was dose-dependent. Finally, in groups that received DOX alone, the high dose blocked both measures of activity whereas the low DOX dose only decreased distance traveled in the expression phase suggestive of a dose-response relationship. Although we did not assess DOX blood levels, it is unlikely that attenuation of COC's effects is due to residual drug because 10 days had elapsed since the last administration. It is more probable that DOX administration prevented long-term neuroplastic changes responsible for COC sensitization (see below). Taken together, these data are consistent with other studies similarly demonstrating that NE, and $\alpha 1$ Rs in particular, are critical in the development and expression of COC-induced locomotor sensitization.

Our results support data from previous studies in rodents showing that pretreatment with the prototypical $\alpha 1$ R antagonist, prazosin, blocks the effects of COC on locomotor activation [21–24,31]. We now extend these findings to the longer-acting $\alpha 1$ R antagonist, DOX. Numerous studies have shown attenuation of the behavioral effects of stimulants, in addition to other drugs of abuse, either by genetic negation (gene knock-outs) or pharmacological blockade of $\alpha 1$ receptors [21–24,31–33]. The ability of DOX to potently attenuate the expression of COC-induced sensitization is also consistent with Salomon *et al.* (2006) who demonstrated similar effects with prazosin on the expression of amphetamine-induced behavioral sensitization following a 1-month withdrawal period [34]. In contrast, one report found no effects of prazosin on sensitization to COC [35].

Prazosin administration also attenuates the ability of COC to support place conditioning [36] and induce COC-seeking in an animal model of relapse [27,36]. The discriminative stimulus effects of COC [37] are reduced and breaking points for COC self-administration decreased by prazosin [25,26,37]. Yet, two reports found no acute effects of prazosin or terazosin (a similar $\alpha 1$ antagonist) on COC self-administration [38,39]. Although species or procedural differences may have contributed to these divergent findings, it is more likely that chronic, not acute, $\alpha 1$ blockade is required to alter COC

self-administration. Indeed, we found that sensitization of COC-self-administration is blocked by prazosin when administered in a similar manner as used within the present study [26]. Nevertheless, our data are still consistent with the idea that chronic α 1R blockade is required to appreciably attenuate stimulant-induced effects on behavior. That is, acute DOX administration did not alter COC-induced locomotor activation (Figure 1, Day 1) whereas chronic treatment significantly attenuated the development (Days 2–5) and expression of COC sensitization (Figure 2) that was more profoundly demonstrated on vertical compared to horizontal measures (Figures 1B and 2B).

The ability of DOX to block the development and expression of COC sensitization was more robustly seen on vertical compared to horizontal activity measures. Vertical activity is generally considered a measure of stereotypy, or non-purposeful repetitive behaviors (rearing, sniffing and head-bobbing) commonly seen in rodents following stimulant administration. The mechanism(s) responsible for the specific effect of DOX on vertical behavior are unknown but may relate to the neuroanatomical distribution of α 1Rs in motor circuits. Preclinical studies associate increased DA levels in the dorsal striatum/mPFC [40,41] and dis-regulated inhibitory/excitatory influence of neurons that project to the substantia nigra with COC-induced stereotypy [42,43]. α 1Rs are located on pre and post-synaptic elements in the substantia nigra [44] where adrenergic agonists activate nigral neurons which is blocked by prazosin [45]. Therefore, the ability of DOX to attenuate COC-induced stereotypy measures more robustly found in the present study may relate to action at α 1 receptors located in multiple brain areas (PFC and substantia nigra) that mediate this behavior. Further studies are needed to assess whether blockade of the development and expression of COC-induced stereotypy specifically, is a better indicator of possible pharmacotherapies for COC-dependence.

Disulfiram is a medication indicated for alcohol-use disorder yet numerous clinical studies have shown it modestly decreases COC use in COC-dependent individuals regardless of alcohol status [46]. We previously utilized the same behavioral protocol used in the present study to assess the effects of disulfiram on COC locomotor sensitization [30]. In contrast to DOX, disulfiram *increased* the development and expression of COC locomotor-sensitization. The mechanism responsible for the divergent effects produced by DOX and disulfiram on COC-locomotor sensitization is unknown but may be explained, in part, by dose of each drug tested and disulfiram's complex peripheral and central pharmacological actions [47]. Regarding dose, similar to disulfiram, we found that the low dose of DOX (0.3 mg/kg) administered alone during the developmental phase appeared to pre-sensitize rats (Figure 2B). The higher DOX dose (1.0 mg/kg) however completely blocked the expression of COC-sensitization. Similar to disulfiram, DOX effects were more readily seen on vertical count measures [30]. Studies in humans also support the notion that the ability of disulfiram treatment to decrease COC's reinforcing effects is dose dependent. Indeed, results from a laboratory-based within-subjects clinical trial indicate that lower doses of disulfiram based on a mg/kg bases increased, whereas higher doses decreased choices for cocaine [48]. These results are consistent with a recent out-patient clinical trial showing that low doses (62.5 mg/day) of disulfiram also increased, whereas higher doses (250 mg/day) slightly decreased COC use [49]. By way of copper chelation, disulfiram and its metabolite, diethyldithiocarbamate inhibit numerous peripheral and central enzymes involved in the metabolism and reinforcing effects of COC including dopamine- β hydroxylase leading to increases in DA and decreases in NE [17]. Serotonin neurotransmission and receptor levels are also increased with disulfiram treatment [50,51]. Recent studies also suggest that acute disulfiram

administration can augment COC-induced increases in PFC DA [52]. In contrast to the non-specific effects of disulfiram, DOX almost exclusively targets $\alpha 1$ receptors [28]. Taken together, it is likely dose and mechanisms of action particular to DOX and disulfiram that contribute to their divergent effects on COC sensitization.

Enduring neuroplastic changes within mesocorticolimbic circuitry are believed to contribute to the long-lasting behavioral effects observed in COC sensitization [53,54]. COC-induced neural changes target DAergic projections from the VTA to the NAc and PFC as well as glutamatergic input acting through α -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors from the PFC to the VTA and NAc [55–58]. All of these structures receive ample NEergic input from medullary NE cell bodies and the LC [59,60]. Recent studies have localized $\alpha 1$ receptors within mesocorticolimbic circuitry clarifying their complex interaction with neurotransmitters DA and glutamate known to contribute to stimulant-induced sensitization [61–63]. For example, activation of pre-synaptic $\alpha 1$ Rs on PFC terminals in the VTA enhances glutamate release onto presumed DA-containing neurons and this effect is blocked by prazosin [63]. NE-induced activation of $\alpha 1$ Rs within the PFC also increases DA, an effect that is facilitated by the adrenergic agonist phenylephrine and blocked by prazosin [64]. $\alpha 1$ R antagonism within the NAc also attenuates COC-induced increases in DA levels and behavioral activation [61]. Taken together, the present study is congruent with numerous studies demonstrating the critical importance of NE, acting through $\alpha 1$ Rs, in augmenting and controlling central DA neurotransmission as well as affecting neural circuits that alter the behavioral effects of stimulants in animals [19–21,65–70].

$\alpha 1$ Rs are primarily localized on pre-synaptic elements in the VTA, NAc and PFC but some may be located post-synaptically in the NAc [44,61,62]. This neuroanatomical distribution allows NE, acting through $\alpha 1$ Rs, to influence DA neurotransmission by way of numerous mechanisms [20,44,61–63]. Accordingly, dosing regimens of COC that induce sensitization potentially increase $\alpha 1$ Rs in limbic brain regions presumably to accommodate COC-induced increases in DA [70]. This suggests that long-lasting drug-induced neuroplastic changes associated with the expression of stimulant sensitization may be mediated, in part, through $\alpha 1$ Rs. The present study is consistent with others demonstrating that $\alpha 1$ R blockade prevents the expression of stimulant-induced sensitization even after an extended withdrawal period [34]. Taken together, evidence supports the conclusion that antagonism at $\alpha 1$ Rs with DOX targets different brain areas to influence many pathways and neurotransmitter systems known to mediate stimulant-induced effects. Further studies investigating molecular machinery responsible for DOX's ability to attenuate COC's behavioral effects are needed.

3. Material and Methods

3.1. Animals

Adult male Sprague–Dawley rats ($n = 6–8$ /group, Harlan Sprague-Dawley Inc., Indianapolis, IN, USA) were used in this study. Rats were housed three per cage in polypropylene cages in a temperature- and humidity-controlled room maintained on a 12:12 light/dark cycle (lights on at 7:00). Food and water were available *ad libitum*. Protocols were approved by the Baylor College of Medicine Institutional Animal Care and Use Committee and followed the “Principles of Laboratory Animal

Care” (NIH publication No.85-23, revised 1996). Facilities were accredited by the American Association of Laboratory Animal Care.

3.2. Test Apparatus

The TruScan photobeam activity system (Coulbourn Instruments, Allentown, PA, USA) was used to measure horizontal and vertical distance traveled in centimeters. This system consisted of a clear arena (16”L × 16”W × 15.5”D) that had two sets of infrared sensors with one located at floor level and the other 2.5” above floor level. Data from beam breaks were tabulated and analyzed by a PC computer and using a Coulbourn Instruments software system (TruScan 2.03).

3.3. Drugs

Cocaine HCl (National Institute on Drug Abuse, Research Triangle Park, NC, USA) and DOX (Sigma-Aldrich, St Louis, MO, USA) were prepared in sterile saline and administered IP in a volume of 1 mg/mL by body weight (kg). Drug solutions were prepared fresh daily.

3.4. Groups

To test the effects of DOX on locomotor sensitization to cocaine, six groups of rats ($n = 6-8$ per group) were employed. Groups included vehicle (saline), cocaine (10 mg/kg), DOX (0.3 and 1.0 mg/kg) and DOX + cocaine. Pretreatment time was 30 min for DOX. The dose range for DOX was chosen based on our previous studies showing that 0.3 mg/kg prazosin, a similar compound to DOX but with a lower half-life, blocked drug-induced relapse to cocaine seeking in rats [27]. A higher DOX dose was chosen based on a human clinical trial [29].

3.5. Locomotor Sensitization Procedure

Assessment of locomotor sensitization to cocaine was performed in a similar manner as before [30]. Rats were randomly divided into groups then administered saline, and habituated to the apparatus for 60-min daily until baseline accumulative measures did not significantly differ. The development test phase began on the next day (day 1) when rats were administered drugs according to group and immediately placed in the activity chambers for 60-min. This same procedure was followed for the next four consecutive days (days 2–5). The expression test phase was conducted 10 days later (Day 15) following a drug “washout” period when no drug administration occurred. On day 15, all rats from all six groups received cocaine injections (10 mg/kg) and activity levels were measured as before.

3.6. Data Analysis

Distance traveled (cm), which reflects ambulatory activity, was the primary endpoint analyzed. Habituation locomotor activity was assessed using a two-way ANOVA (COC dose × DOX dose). Data from the development phase (days 1–5) of the locomotor study were analyzed with a $2 \times 3 \times 5$ repeated measures ANOVA with treatment dose of cocaine (0, 10 mg/kg) and DOX dose (0, 0.3, 1.0 mg/kg) as the main factors with repeated measures over days. Because there were slight group differences in baseline activity, these measures were incorporated into an Analysis of

Co-variance. Acute effects of cocaine (day 1) among the groups were analyzed separately with a 2×3 ANOVA representing between group factors of cocaine dose and DOX dose. Data from the expression phase (day 15) were also analyzed with a 2×3 ANOVA. When applicable, significant main effects were followed by *post-hoc* analysis with Newman-Keuls tests. Data are presented as mean \pm SEM and significant *p* values set at <0.05 .

4. Conclusions

We recently demonstrated that DOX blocked COC's positive subjective effects (e.g., "high", "stimulated", "like cocaine" and "desire cocaine") in non-treatment seeking, COC-dependent individuals [29]. This suggests that the basic locomotor sensitization paradigm employed in this study may have predictive validity in assessing possible pharmacotherapies for COC dependence in humans. Based on this assumption, medications that both attenuate the *development* (specifically vertical activity) and *expression* of COC-induced behavioral sensitization may be characteristics of potential pharmacotherapeutic agents for COC-dependence in humans. DOX in particular also possesses a number of beneficial pharmacological characteristics that make it a promising pharmacotherapy. For example, DOX is: (1) presently indicated for the treatment of hypertension; (2) is cardio-renal-protective; and (3) has few known drug interactions [71,72]. More importantly, DOX blocks the hypertensive and positive subjective effects of COC in humans [29]. Taken together, the present study highlights the importance of $\alpha 1$ Rs in the behavioral effects of COC and supports further research and development of DOX as a treatment for COC-dependence in humans.

Acknowledgments

This research was supported by grant U01 AA13476.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Gatley, S.J.; Logan, J. [(11)C]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. *Nucl. Med. Biol.* **2001**, *28*, 561–572.
2. Rothman, R.B.; Baumann, M.H.; Dersch, C.M.; Romero, D.V.; Rice, K.C.; Carroll, F.I.; Partilla, J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. *Synapse* **2001**, *39*, 32–41.
3. Di Chiara, G.; Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc. Natl. Acad. Sci. USA* **1988**, *85*, 5274–5278.
4. Pettit, H.O.; Ettenberg, A.; Bloom, F.E.; Koob, G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. *Psychopharmacology* **1984**, *84*, 167–173.

5. Ritz, M.C.; Lamb, R.J.; Goldberg, S.R.; Kuhar, M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. *Science* **1987**, *237*, 1219–1223.
6. Kalivas, P.W.; Stewart, J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. *Brain Res. Brain Res. Rev.* **1991**, *16*, 223–244.
7. Robinson, T.E.; Berridge, K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. *Brain Res. Brain Res. Rev.* **1993**, *18*, 247–291.
8. Small, A.C.; Kampman, K.M.; Plebani, J.; De Jesus Quinn, M.; Peoples, L.; Lynch, K.G. Tolerance and sensitization to the effects of cocaine use in humans: A retrospective study of long-term cocaine users in Philadelphia. *Subst. Use Misuse* **2009**, *44*, 1888–1898.
9. Haile, C.N.; Mahoney, J.J., 3rd; Newton, T.F.; de La Garza, R., II. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: Focus on dopamine, norepinephrine and glutamate. *Pharmacol. Ther.* **2012**, *134*, 260–277.
10. Weinshenker, D.; Schroeder, J.P. There and back again: A tale of norepinephrine and drug addiction. *Neuropsychopharmacology* **2007**, *32*, 1433–1451.
11. Delfs, J.M.; Zhu, Y.; Druhan, J.P.; Aston-Jones, G.S. Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: Anterograde and retrograde tract-tracing studies in the rat. *Brain Res.* **1998**, *806*, 127–140.
12. Devoto, P.; Flore, G.; Pani, L.; Gessa, G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. *Mol. Psychiatry* **2001**, *6*, 657–664.
13. Moron, J.A.; Brockington, A.; Wise, R.A.; Rocha, B.A.; Hope, B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. *J. Neurosci.* **2002**, *22*, 389–395.
14. Mohammed, A.K.; Danysz, W.; Ogren, S.O.; Archer, T. Central noradrenaline depletion attenuates amphetamine-induced locomotor behavior. *Neurosci. Lett.* **1986**, *64*, 139–144.
15. Murase, S.; Grenhoff, J.; Chouvet, G.; Gonon, F.G.; Svensson, T.H. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied *in vivo*. *Neurosci. Lett.* **1993**, *157*, 53–56.
16. Ventura, R.; Morrone, C.; Puglisi-Allegra, S. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 5181–5186.
17. Gaval-Cruz, M.; Weinshenker, D. Mechanisms of disulfiram-induced cocaine abstinence: Antabuse and cocaine relapse. *Mol. Interv.* **2009**, *9*, 175–187.
18. Pani, P.P.; Trogu, E.; Vacca, R.; Amato, L.; Vecchi, S.; Davoli, M. Disulfiram for the treatment of cocaine dependence. *Cochrane Database Syst. Rev.* **2010**, doi:10.1002/14651858.CD007024.pub2.
19. Blanc, G.; Trovero, F.; Vezina, P.; Herve, D.; Godeheu, A.M.; Glowinski, J.; Tassin, J.P. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. *Eur. J. Neurosci.* **1994**, *6*, 293–298.
20. Darracq, L.; Blanc, G.; Glowinski, J.; Tassin, J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. *J. Neurosci.* **1998**, *18*, 2729–2739.
21. Drouin, C.; Darracq, L.; Trovero, F.; Blanc, G.; Glowinski, J.; Cotecchia, S.; Tassin, J.P. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. *J. Neurosci.* **2002**, *22*, 2873–2884.

22. Jimenez-Rivera, C.A.; Feliu-Mojer, M.; Vazquez-Torres, R. Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. *Ann. N. Y. Acad. Sci.* **2006**, *1074*, 390–402.
23. Snoddy, A.M.; Tessel, R.E. Prazosin: Effect on psychomotor-stimulant cues and locomotor activity in mice. *Eur. J. Pharmacol.* **1985**, *116*, 221–228.
24. Wellman, P.; Ho, D.; Cepeda-Benito, A.; Bellinger, L.; Nation, J. Cocaine-induced hypophagia and hyperlocomotion in rats are attenuated by prazosin. *Eur. J. Pharmacol.* **2002**, *455*, 117–126.
25. Wee, S.; Mandyam, C.D.; Lekic, D.M.; Koob, G.F. Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. *Eur. Neuropsychopharmacol.* **2008**, *18*, 303–311.
26. Zhang, X.Y.; Kosten, T.A. Previous exposure to cocaine enhances cocaine self-administration in an alpha 1-adrenergic receptor dependent manner. *Neuropsychopharmacology* **2007**, *32*, 638–645.
27. Zhang, X.Y.; Kosten, T.A. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. *Biol. Psychiatry* **2005**, *57*, 1202–1204.
28. Elliott, H.L.; Meredith, P.A.; Sumner, D.J.; McLean, K.; Reid, J.L. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. *Br. J. Clin. Pharmacol.* **1982**, *13*, 699–703.
29. Newton, T.F.; De La Garza, R., 2nd; Brown, G.; Kosten, T.R.; Mahoney, J.J., 3rd; Haile, C.N. Noradrenergic alpha(1) receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: A randomized trial. *PloS One* **2012**, *7*, e30854.
30. Haile, C.N.; Daring, M.J.; Jatlow, P.I.; Kosten, T.R.; Kosten, T.A. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. *Biol. Psychiatry* **2003**, *54*, 915–921.
31. Berthold, C.W., 3rd; Gonzales, R.A.; Moerschbaecher, J.M. Prazosin attenuates the effects of cocaine on motor activity but not on schedule-controlled behavior in the rat. *Pharmacol. Biochem. Behav.* **1992**, *43*, 111–115.
32. Selken, J.; Nichols, D.E. Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. *Pharmacol. Biochem. Behav.* **2007**, *86*, 622–630.
33. Verplaetse, T.L.; Rasmussen, D.D.; Froehlich, J.C.; Czachowski, C.L. Effects of prazosin, an alpha1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. *Alcohol. Clin. Exp. Res.* **2012**, *36*, 881–886.
34. Salomon, L.; Lanteri, C.; Glowinski, J.; Tassin, J.P. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 7476–7481.
35. Vanderschuren, L.J.; Beemster, P.; Schoffelmeer, A.N. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. *Psychopharmacology* **2003**, *169*, 176–185.
36. Bernardi, R.E.; Ryabinin, A.E.; Berger, S.P.; Lattal, K.M. Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta2- and alpha1-adrenergic antagonists. *Learn. Mem.* **2009**, *16*, 777–789.

37. Spealman, R.D. Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. *J. Pharmacol. Exp. Ther.* **1995**, *275*, 53–62.
38. Ecke, L.E.; Elmer, G.I.; Suto, N. Cocaine self-administration is not dependent upon mesocortical alpha1 noradrenergic signaling. *Neuroreport* **2012**, *23*, 325–330.
39. Woolverton, W.L. Evaluation of the role of norepinephrine in the reinforcing effects of psychomotor stimulants in rhesus monkeys. *Pharmacol. Biochem. Behav.* **1987**, *26*, 835–839.
40. Kelly, P.H.; Seviour, P.W.; Iversen, S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. *Brain Res.* **1975**, *94*, 507–522.
41. Saka, E.; Goodrich, C.; Harlan, P.; Madras, B.K.; Graybiel, A.M. Repetitive behaviors in monkeys are linked to specific striatal activation patterns. *J. Neurosci.* **2004**, *24*, 7557–7565.
42. Aliane, V.; Perez, S.; Nieoullon, A.; Deniau, J.M.; Kemel, M.L. Cocaine-induced stereotypy is linked to an imbalance between the medial prefrontal and sensorimotor circuits of the basal ganglia. *Eur. J. Neurosci.* **2009**, *30*, 1269–1279.
43. Saxena, S.; Brody, A.L.; Schwartz, J.M.; Baxter, L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Br. J. Psychiatry Suppl.* **1998**, *173*, 26–37.
44. Rommelfanger, K.S.; Mitrano, D.A.; Smith, Y.; Weinshenker, D. Light and electron microscopic localization of alpha-1 adrenergic receptor immunoreactivity in the rat striatum and ventral midbrain. *Neuroscience* **2009**, *158*, 1530–1540.
45. Berretta, N.; Bernardi, G.; Mercuri, N.B. Alpha(1)-adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons. *Neuroscience* **2000**, *98*, 599–604.
46. Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; O'Brien, C.P. The status of disulfiram: A half of a century later. *J. Clin. Psychopharmacol.* **2006**, *26*, 290–302.
47. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. *Acta Psychiatr. Scand. Suppl.* **1992**, *369*, 15–26.
48. Haile, C.N.; De La Garza, R., 2nd; Mahoney, J.J.; Nielsen, D.A.; Kosten, T.R.; Newton, T.F. The impact of disulfiram treatment on the reinforcing effects of cocaine. *PloS One*, 2012, in press.
49. Oliveto, A.; Poling, J.; Mancino, M.J.; Feldman, Z.; Cubells, J.F.; Pruzinsky, R.; Gonsai, K.; Cargile, C.; Sofuoglu, M.; Chopra, M.P.; *et al.* Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. *Drug Alcohol Depend.* **2011**, *113*, 184–191.
50. Beck, O.; Borg, S.; Holmstedt, B.; Kvande, H.; Shroder, R. Concentration of serotonin metabolites in the cerebrospinal fluid from alcoholics before and during disulfiram therapy. *Acta Pharmacol. Toxicol. (Copenh.)* **1980**, *47*, 305–307.
51. Ryu, Y.H.; Liow, J.S.; Zoghbi, S.; Fujita, M.; Collins, J.; Tipre, D.; Sangare, J.; Hong, J.; Pike, V.W.; Innis, R.B. Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. *J. Nucl. Med.* **2007**, *48*, 1154–1161.
52. Devoto, P.; Flore, G.; Saba, P.; Cadeddu, R.; Gessa, G.L. Disulfiram stimulates dopamine release from noradrenergic terminals and potentiates cocaine-induced dopamine release in the prefrontal cortex. *Psychopharmacology* **2012**, *219*, 1153–1164.

53. Boudreau, A.C.; Wolf, M.E. Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. *J. Neurosci.* **2005**, *25*, 9144–9151.
54. Russo, S.J.; Dietz, D.M.; Dumitriu, D.; Morrison, J.H.; Malenka, R.C.; Nestler, E.J. The addicted synapse: Mechanisms of synaptic and structural plasticity in nucleus accumbens. *Trends Neurosci.* **2010**, *33*, 267–276.
55. Carr, D.B.; O'Donnell, P.; Card, J.P.; Sesack, S.R. Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. *J. Neurosci.* **1999**, *19*, 11049–11060.
56. Ghasemzadeh, M.B.; Mueller, C.; Vasudevan, P. Behavioral sensitization to cocaine is associated with increased glutamate receptor trafficking to the postsynaptic density after extended withdrawal period. *Neuroscience* **2009**, *159*, 414–426.
57. Sesack, S.R.; Pickel, V.M. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. *J. Comp. Neurol.* **1992**, *320*, 145–160.
58. Wolf, M.E.; Ferrario, C.R. AMPA receptor plasticity in the nucleus accumbens after repeated exposure to cocaine. *Neurosci. Biobehav. Rev.* **2010**, *35*, 185–211.
59. Jones, B.E.; Moore, R.Y. Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study. *Brain Res.* **1977**, *127*, 25–53.
60. Mejias-Aponte, C.A.; Drouin, C.; Aston-Jones, G. Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: Prominent inputs from medullary homeostatic centers. *J. Neurosci.* **2009**, *29*, 3613–3626.
61. Mitrano, D.A.; Schroeder, J.P.; Smith, Y.; Cortright, J.J.; Bubula, N.; Vezina, P.; Weinschenker, D. Alpha-1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. *Neuropsychopharmacology* **2012**, *37*, 2161–2172.
62. Saigusa, T.; Aono, Y.; Uchida, T.; Takada, K.; Verheij, M.M.; Koshikawa, N.; Cools, A.R. The alpha(1)-, but not alpha(2)-, adrenoceptor in the nucleus accumbens plays an inhibitory role upon the accumbal noradrenaline and dopamine efflux of freely moving rats. *Eur. J. Pharmacol.* **2012**, in press.
63. Velasquez-Martinez, M.C.; Vazquez-Torres, R.; Jimenez-Rivera, C.A. Activation of alpha1-adrenoceptors enhances glutamate release onto ventral tegmental area dopamine cells. *Neuroscience* **2012**, *216*, 18–30.
64. Pan, W.H.; Yang, S.Y.; Lin, S.K. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. *Synapse* **2004**, *53*, 44–52.
65. Sommermeyer, H.; Frielingsdorf, J.; Knorr, A. Effects of prazosin on the dopaminergic neurotransmission in rat brain. *Eur. J. Pharmacol.* **1995**, *276*, 267–270.
66. Ventura, R.; Cabib, S.; Alcaro, A.; Orsini, C.; Puglisi-Allegra, S. Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. *J. Neurosci.* **2003**, *23*, 1879–1885.
67. Villegier, A.S.; Drouin, C.; Bizot, J.C.; Marien, M.; Glowinski, J.; Colpaert, F.; Tassin, J.P. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. *Synapse* **2003**, *50*, 277–284.

68. Zhou, Y.; Bunney, B.S.; Shi, W.X. Differential effects of cocaine on firing rate and pattern of dopamine neurons: Role of alpha1 receptors and comparison with l-dopa and apomorphine. *J. Pharmacol. Exp. Ther.* **2006**, *317*, 196–201.
69. Auclair, A.; Drouin, C.; Cotecchia, S.; Glowinski, J.; Tassin, J.P. 5-HT_{2A} and alpha_{1b}-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. *Eur. J. Neurosci.* **2004**, *20*, 3073–3084.
70. Nalepa, I.; Witariski, T.; Kowalska, M.; Filip, M.; Vetulani, J. Effect of cocaine sensitization on alpha₁-adrenoceptors in brain regions of the rat: An autoradiographic analysis. *Pharmacol. Rep.* **2006**, *58*, 827–835.
71. Mori, Y.; Matsubara, H.; Nose, A.; Shibasaki, Y.; Masaki, H.; Kosaki, A.; Okigaki, M.; Fujiyama, S.; Tanaka-Uchiyama, Y.; Hasegawa, T.; *et al.* Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. *Hypertens. Res.* **2001**, *24*, 359–363.
72. Wykretowicz, A.; Guzik, P.; Wysocki, H. Doxazosin in the current treatment of hypertension. *Expert Opin. Pharmacother.* **2008**, *9*, 625–633.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).